CClinicalTrials.gg
RecruitingNCT05931562NMBUpdated Jul 16, 2024

The Impact of Diet on the Gut-Microbiota-Brain Axis

An interventional study of Fermented Foods and High Fibre in Healthy, sponsored by University College Cork. Recruiting at 1 site in Ireland. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by University College Cork · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Jul 2022, registered Jun 2023).
  • Started Jul 2022; still recruiting 4 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study aims to investigate the effects of an 8-week dietary intervention on cognitive function, stress, and the gut microbiota in healthy adults with low fibre intake.

Read the detailed description

The gut microbiota communicates bidirectionally with the brain via the microbiota-gut-brain axis to influence various aspects of human physiology, including host metabolism, immune function, behaviour, and cognition. Diet is a key modulator of the microbial composition, suggesting that the microbiota could explain the association between poor nutrition and decreasing health of the population. Dietary fibre is the main energy source for the gut microbiota and fundamentally impacts its composition and function. The microbiota-gut-brain axis has been proposed to mediate some of the effects of dietary fibre on the brain, for example through microbial metabolites (e.g., short-chain fatty acids (SCFA)), regulation of the immune system, and the microbial impact on gut hormones and neurotransmitters. Similarly, intake of fermented foods is positively associated with cognitive health and has been shown to alter the microbiota composition and function and exert an anti-inflammatory effect. However, no studies to date have examined the singular and combined effects of fermented and fibrous foods on the gut microbiota, cognition, and emotion. The present study aims to determine the role of diet on the microbiota-gut-brain axis and mental health.

Using a randomized-controlled, parallel, single-blinded design, participants consuming a habitually low fibre diet (N=200) will undergo an 8-week dietary intervention. Participants will receive one of four diets (n=50 in each group): high fibre (aim 24-35 grams/day), fermented foods (aim 4-6 portions/day), combined diet of fermented foods and high fibre (aim 25-30g/day of fibre and 3-4 servings/day of fermented foods) or control (dietary education according to national Irish guidelines). Cognitive, psychological, and biological measures will be compared at baseline and endpoint. During the intervention period, individuals will provide repeated faecal samples to assess temporal microbial changes.

02

Conditions studied

  • Healthy

Keywords

  • Microbiota-gut-brain axis
  • Diet
  • Cognition
  • Stress
  • Dietary Fibre
  • Fermented foods
03

In context

Lead sponsor

University College Cork is the lead sponsor of 116 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Be able to give written informed consent.
  • Be between 18 and 50 years of age.
  • Have a body mass index (BMI) between 18.5-29.9 Kg/m2.
  • Be in generally good health as determined by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Are less than 18 and greater than 50 years of age.
  • Have a BMI below 18.5 or above 29.9 Kg/m2.
  • Have a significant acute or chronic coexisting illness [cardiovascular, gastrointestinal (GI) [to include functional GI disorders, inflammatory bowel disease, coeliac disease, lactose intolerance, food allergies], immunological, psychiatric [to include formal or as determined by MINI Psychiatric interview, diagnosis of current major depression, anxiety disorder, bipolar spectrum disorder, schizophrenia, other DSM-IV Axis I disorder], neurodevelopmental disorders, immunological, metabolic disorders [to include type I or II diabetes], or any condition which contraindicates, in the investigators judgement, entry to the study,
  • Have a condition or taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk, or confound the interpretation of the study results; all psychoactive medications [to include anxiolytics, antipsychotics, antidepressants, anticonvulsants, centrally acting corticosteroids, and opioid pain relievers), laxatives, enemas, antibiotics, anti-coagulants, over-the counter non-steroidal anti-inflammatories (NSAIDS). Subjects should have a wash-out period of 4 weeks.
  • Current prebiotic or probiotic supplement use (a wash-out period of 4 weeks after cessation will allow entry to the study).
  • Females who are peri-menopausal, menopausal or post-menopausal.
  • Females who are pregnant or planning a pregnancy, or lactating.
  • Participants who are not fluent in English.
  • Are colour blind.
  • Have dyslexia or dyscalculia.
  • Are a current habitual daily smoker.
  • Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
  • Subjects receiving treatment involving experimental drugs. If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.
  • Have a malignant disease or any concomitant end-stage organ disease.
  • Have completed a study in our laboratory in the past 4 years.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Participant)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Control

    Participants will recieve dietary education based on the healthy eating guidleines provided by the Health Service Executive (HSE).

    Other: Control

  • Experimental
    Fermented Foods

    Fermented foods diet (4-6 portions/day)

    Other: Fermented Foods

  • Experimental
    High Fibre

    High fibre diet (24-35 grams/day)

    Other: High Fibre

  • Experimental
    Combined Diet

    Combined diet high in fibre and fermented foods (fibre aim 24-35 grams/day, fermented foods aim 4-6 portions/day)

    Other: Combined Diet

Interventions

  • OtherFermented Foods

    Participants will recieve dietary education to include 4 to 6 portions of fermented foods to their normal diet.

  • OtherHigh Fibre

    Participants will recieve dietary education to increase their fibre intake to 24-35g/day in their normal diet.

  • OtherCombined Diet

    Participants will recieve dietary education to increase their fibre intake to 25-30g/day and include 3 to 4 portions of fermented foods to their normal diet.

  • OtherControl

    Participants will recieve dietary education based on the Irish healthy food pyramid.

06

What researchers measure

Primary outcomes

  1. Trait stress/mood: self-report

    self-report questionnaires

    Time frame: Change from baseline at 8 weeks

  2. Trait stress/mood: hypothalamic-pituitary-adrenal axis activity

    Cortisol from saliva samples

    Time frame: Change from baseline at 8 weeks

  3. Responses to acute stress: self-report

    Self-report questionnaires

    Time frame: Change from baseline at 8 weeks

  4. Responses to acute stress: sympathetic-adrenal-medullary pathway activity

    Galvanic skin response taken from the skin on the hand

    Time frame: Change from baseline at 8 weeks

  5. Responses to acute stress: hypothalamic-pituitary-adrenal axis activity

    Cortisol from saliva samples

    Time frame: Change from baseline at 8 weeks

Secondary outcomes

  1. Cognitive performance: working memory

    Spatial Working Memory

    Time frame: Change from baseline at 8 weeks

  2. Cognitive performance: episodic memory

    Modified Rey Auditory Verbal Learning Test (ModRey)

    Time frame: Change from baseline at 8 weeks

  3. Cognitive performance: decision making

    Iowa Gambling Task

    Time frame: Change from baseline at 8 weeks

  4. Cognitive performance: emotional inhibition

    Emotional Stroop

    Time frame: Change from baseline at 8 weeks

  5. Cognitive performance: sustained attention

    Rapid Visual Information Processing

    Time frame: Change from baseline at 8 weeks

  6. Cognitive performance: visual pattern recognition memory

    Pattern Recognition Memory

    Time frame: Change from baseline at 8 weeks

  7. Cognitive performance: cognitive flexibility

    Intra-Extra Dimensional Set Shifting

    Time frame: Change from baseline at 8 weeks

  8. Cognitive performance: social cognition

    Emotion Recognition Task

    Time frame: Change from baseline at 8 weeks

  9. Cognitive performance: affective perceptual bias

    Emotional Bias Task

    Time frame: Change from baseline at 8 weeks

  10. Microbiota composition and function

    Shotgun metagenomics of fecal samples

    Time frame: Change from baseline at 8 weeks

  11. Microbial and host metabolomics

    Untargeted metabolomics analysis

    Time frame: Change from baseline at 8 weeks

  12. Inflammation

    Inflammatory markers in lipopolysaccharide stimulated and unstimulated bloods

    Time frame: Change from baseline at 8 weeks

07

Study locations

1 of 1 sites recruiting
  • APC Microbiome Ireland
    Cork, T12YT20, Ireland
    • Revathy Munuswamy, PhD · Contact · RMunuswamy@ucc.ie · (+353) 021 4901721
    • John F Cryan, PhD · Principal investigator
    • Gerard Clarke, PhD · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05931562
Lead sponsor
University College Cork
Responsible party
Sponsor
First posted
Jul 5, 2023
Start date
Jul 14, 2022
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jul 16, 2024

Study contacts

Elizabeth Schneider, PhD
Contact
eschneider@ucc.ie
(+353) 021 4901721
Revathy Munuswamy
Contact
RMunuswamy@ucc.ie
John Cryan, PhD
principal investigator · APC Microbiome Ireland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion